The Potential of GLP-1 Therapies One of the most promising advances in addressing these issues is GLP-1 therapy
A randomized, double-blind pilot of IV glutathione (1400 mg three times weekly for four weeks) in 21 Parkinsons patients found the treatment well tolerated but produced no statistically significant improvement in Unified Parkinsons Disease Rating Scale scores
Diabetes Care 22 , 339344 (1999)
Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the Heart and Soul Study
J Translational Med 9:114 Marreiro DDN, Cruz KJC, Morais JBS, Beserra JB, Severo JS, De Oliveira ARS (2017) Zinc and oxidative stress: current mechanisms
Freeman, Optic Neuropathy and Chronic Cyanide Intoxication: A Review, J